On a deal spree, Mallinck­rodt bags Su­cam­po and two late-stage rare dis­ease drugs for $1.2B

The biotech year is end­ing with a light bang on the M&A front.

Suf­fer­ing from a rep based more on ex­ploit­ing mar­kets than de­vel­op­ing new drugs, Mallinck­rodt $MNK is beef­ing up its pipeline of rare dis­ease drugs with the $1.2 bil­lion buy­out of Su­cam­po $SCMP. The deal de­liv­ers one mar­ket­ed drug — Ami­ti­za (lu­bipro­s­tone) for con­sti­pa­tion — as well as two ex­per­i­men­tal ones, both in late-stage de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.